Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 5561 | 25.59 |
09:34 ET | 4398 | 25.861 |
09:36 ET | 1300 | 26.21 |
09:38 ET | 1400 | 26.05 |
09:39 ET | 1300 | 26.06 |
09:41 ET | 709 | 25.86 |
09:43 ET | 1380 | 26 |
09:45 ET | 400 | 25.78 |
09:48 ET | 955 | 25.605 |
09:50 ET | 755 | 25.71 |
09:52 ET | 3786 | 25.65 |
09:54 ET | 1200 | 25.68 |
09:56 ET | 2218 | 25.725 |
09:57 ET | 2565 | 25.77 |
09:59 ET | 900 | 25.83 |
10:01 ET | 1100 | 25.86 |
10:03 ET | 200 | 25.85 |
10:06 ET | 1133 | 25.89 |
10:08 ET | 500 | 25.965 |
10:10 ET | 100 | 26.01 |
10:12 ET | 819 | 25.995 |
10:14 ET | 2200 | 25.945 |
10:15 ET | 966 | 26.01 |
10:17 ET | 600 | 26.01 |
10:19 ET | 1100 | 26.0475 |
10:21 ET | 1115 | 26.03 |
10:24 ET | 2875 | 26.09 |
10:26 ET | 700 | 26.1 |
10:28 ET | 1700 | 26.19 |
10:30 ET | 1889 | 26.11 |
10:32 ET | 1500 | 26.2 |
10:33 ET | 2197 | 26.035 |
10:35 ET | 4183 | 26.028 |
10:37 ET | 1398 | 26.03 |
10:39 ET | 834 | 26 |
10:42 ET | 900 | 25.94 |
10:44 ET | 1800 | 25.83 |
10:46 ET | 1000 | 25.895 |
10:48 ET | 618 | 25.9 |
10:50 ET | 1100 | 25.85 |
10:51 ET | 900 | 25.89 |
10:53 ET | 200 | 25.885 |
10:55 ET | 500 | 25.88 |
10:57 ET | 2900 | 25.83 |
11:00 ET | 1900 | 25.87 |
11:02 ET | 400 | 25.85 |
11:04 ET | 2600 | 25.85 |
11:06 ET | 3073 | 25.91 |
11:08 ET | 200 | 25.95 |
11:09 ET | 400 | 26.02 |
11:11 ET | 2780 | 25.915 |
11:13 ET | 1400 | 25.91 |
11:15 ET | 1200 | 25.9 |
11:18 ET | 512 | 25.87 |
11:20 ET | 1237 | 25.9 |
11:22 ET | 500 | 25.935 |
11:24 ET | 900 | 25.91 |
11:26 ET | 500 | 25.91 |
11:27 ET | 2138 | 25.95 |
11:29 ET | 500 | 25.94 |
11:31 ET | 1400 | 25.94 |
11:33 ET | 700 | 25.9 |
11:36 ET | 700 | 25.92 |
11:38 ET | 200 | 25.94 |
11:40 ET | 400 | 25.89 |
11:42 ET | 900 | 25.87 |
11:44 ET | 985 | 25.9 |
11:45 ET | 800 | 25.86 |
11:47 ET | 100 | 25.885 |
11:49 ET | 2005 | 25.85 |
11:51 ET | 300 | 25.885 |
11:54 ET | 400 | 25.885 |
11:56 ET | 820 | 25.91 |
11:58 ET | 2700 | 25.925 |
12:00 ET | 600 | 25.89 |
12:02 ET | 1700 | 25.955 |
12:03 ET | 500 | 25.935 |
12:05 ET | 300 | 25.93 |
12:07 ET | 400 | 25.95 |
12:09 ET | 1000 | 25.88 |
12:12 ET | 515 | 25.85 |
12:14 ET | 2504 | 25.86 |
12:16 ET | 630 | 25.85 |
12:20 ET | 1372 | 25.865 |
12:21 ET | 400 | 25.85 |
12:23 ET | 300 | 25.88 |
12:25 ET | 1305 | 25.89 |
12:27 ET | 1900 | 25.95 |
12:30 ET | 400 | 26 |
12:32 ET | 600 | 25.96 |
12:36 ET | 1000 | 25.98 |
12:38 ET | 10242 | 25.95 |
12:39 ET | 314 | 25.96 |
12:41 ET | 2148 | 25.91 |
12:43 ET | 300 | 25.915 |
12:45 ET | 2705 | 25.95 |
12:48 ET | 1200 | 25.975 |
12:50 ET | 1583 | 25.88 |
12:52 ET | 1190 | 25.875 |
12:54 ET | 1929 | 25.905 |
12:56 ET | 300 | 25.9 |
12:57 ET | 800 | 25.9 |
12:59 ET | 600 | 25.9 |
01:01 ET | 1700 | 25.88 |
01:03 ET | 1500 | 25.9 |
01:06 ET | 100 | 25.905 |
01:08 ET | 1419 | 25.93 |
01:10 ET | 1593 | 25.97 |
01:12 ET | 200 | 25.955 |
01:14 ET | 600 | 25.95 |
01:15 ET | 871 | 25.95 |
01:17 ET | 100 | 25.965 |
01:19 ET | 900 | 25.95 |
01:21 ET | 4236 | 25.955 |
01:24 ET | 2000 | 25.93 |
01:26 ET | 1886 | 25.92 |
01:28 ET | 3418 | 25.95 |
01:30 ET | 1150 | 25.95 |
01:32 ET | 3100 | 25.87 |
01:33 ET | 1816 | 25.87 |
01:35 ET | 1717 | 25.87 |
01:37 ET | 2000 | 25.91 |
01:39 ET | 27228 | 25.895 |
01:42 ET | 781 | 25.9 |
01:44 ET | 100 | 25.89 |
01:46 ET | 2193 | 25.975 |
01:48 ET | 2350 | 25.98 |
01:50 ET | 2050 | 25.96 |
01:51 ET | 600 | 25.97 |
01:53 ET | 1205 | 25.95 |
01:55 ET | 3845 | 25.95 |
01:57 ET | 200 | 25.95 |
02:00 ET | 746 | 25.955 |
02:02 ET | 1993 | 25.93 |
02:04 ET | 500 | 25.96 |
02:06 ET | 3549 | 25.94 |
02:08 ET | 5025 | 26.06 |
02:09 ET | 2019 | 26.03 |
02:11 ET | 600 | 26.03 |
02:15 ET | 1100 | 26.15 |
02:18 ET | 200 | 26.115 |
02:20 ET | 3065 | 26.155 |
02:22 ET | 237 | 26.155 |
02:24 ET | 2842 | 26.22 |
02:26 ET | 738 | 26.22 |
02:27 ET | 940 | 26.19 |
02:29 ET | 700 | 26.18 |
02:31 ET | 1040 | 26.19 |
02:33 ET | 1200 | 26.16 |
02:36 ET | 145 | 26.16 |
02:38 ET | 2719 | 26.16 |
02:40 ET | 100 | 26.16 |
02:42 ET | 7000 | 26.17 |
02:44 ET | 700 | 26.18 |
02:45 ET | 549 | 26.22 |
02:47 ET | 100 | 26.21 |
02:49 ET | 323 | 26.205 |
02:51 ET | 1437 | 26.2 |
02:54 ET | 633 | 26.245 |
02:56 ET | 1300 | 26.24 |
02:58 ET | 700 | 26.24 |
03:00 ET | 559 | 26.27 |
03:02 ET | 1043 | 26.255 |
03:03 ET | 700 | 26.21 |
03:05 ET | 262 | 26.2 |
03:07 ET | 1051 | 26.26 |
03:09 ET | 400 | 26.24 |
03:12 ET | 1308 | 26.18 |
03:14 ET | 2300 | 26.21 |
03:16 ET | 700 | 26.19 |
03:18 ET | 700 | 26.155 |
03:20 ET | 755 | 26.15 |
03:21 ET | 1900 | 26.17 |
03:23 ET | 900 | 26.21 |
03:25 ET | 606 | 26.23 |
03:27 ET | 1334 | 26.265 |
03:30 ET | 2171 | 26.25 |
03:32 ET | 1600 | 26.24 |
03:34 ET | 1091 | 26.18 |
03:36 ET | 615 | 26.19 |
03:38 ET | 1422 | 26.185 |
03:39 ET | 2350 | 26.22 |
03:41 ET | 1600 | 26.23 |
03:43 ET | 1500 | 26.23 |
03:45 ET | 2549 | 26.23 |
03:48 ET | 300 | 26.22 |
03:50 ET | 4354 | 26.22 |
03:52 ET | 39917 | 26.46 |
03:54 ET | 6779 | 26.42 |
03:56 ET | 17284 | 26.52 |
03:57 ET | 45780 | 26.4 |
03:59 ET | 34738 | 26.4 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 3.9B | -14.0x | --- |
Crinetics Pharmaceuticals Inc | 3.5B | -11.9x | --- |
Dyne Therapeutics Inc | 3.5B | -8.9x | --- |
Merus NV | 4.0B | -21.7x | --- |
Immunitybio Inc | 4.4B | -6.0x | --- |
Avidity Biosciences Inc | 4.3B | -13.9x | --- |
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-1.89 |
Book Value | $4.24 |
P/E Ratio | -14.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.